These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 9045306)
21. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. Yanada M; Takeuchi J; Sugiura I; Akiyama H; Usui N; Yagasaki F; Kobayashi T; Ueda Y; Takeuchi M; Miyawaki S; Maruta A; Emi N; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R; J Clin Oncol; 2006 Jan; 24(3):460-6. PubMed ID: 16344315 [TBL] [Abstract][Full Text] [Related]
22. Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system. Harker-Murray PD; Thomas AJ; Wagner JE; Weisdorf D; Luo X; DeFor TE; Verneris MR; Dusenbery KE; MacMillan ML; Tolar J; Baker KS; Orchard PJ Biol Blood Marrow Transplant; 2008 Jun; 14(6):685-92. PubMed ID: 18489994 [TBL] [Abstract][Full Text] [Related]
23. [Acute lymphoblastic leukemia (ALL)]. Imai K; Akiyama H Gan To Kagaku Ryoho; 2007 Dec; 34(13):2180-4. PubMed ID: 18079617 [TBL] [Abstract][Full Text] [Related]
24. [Prognostic factors for childhood acute non-mature B-lymphoblastic leukemia]. Jiang H; Gu LJ; Xue HL; Tang JY; Chen J; Pan C; Chen J; Xu C; Dong L; Zhou M Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):290-4. PubMed ID: 18554450 [TBL] [Abstract][Full Text] [Related]
25. [Use of monoclonal antibodies in acute lymphoblastic leukemia in children. II. Clinical picture and prognosis in specific immunological subgroups]. Kołecki P; Radwańska U Pediatr Pol; 1988 Nov; 63(11):698-702. PubMed ID: 3253656 [No Abstract] [Full Text] [Related]
26. [Recent progress in the treatment of acute leukemia]. Kimura Y Gan To Kagaku Ryoho; 2003 Jul; 30(7):895-901. PubMed ID: 12894700 [TBL] [Abstract][Full Text] [Related]
27. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Ottmann OG; Wassmann B; Pfeifer H; Giagounidis A; Stelljes M; Dührsen U; Schmalzing M; Wunderle L; Binckebanck A; Hoelzer D; Cancer; 2007 May; 109(10):2068-76. PubMed ID: 17429836 [TBL] [Abstract][Full Text] [Related]
28. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial. Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF; Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166 [TBL] [Abstract][Full Text] [Related]
29. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. Sancho JM; Ribera JM; Xicoy B; Morgades M; Oriol A; Tormo M; del Potro E; Debén G; Abella E; Bethencourt C; Ortín X; Brunet S; Ortega-Rivas F; Novo A; López R; Hernández-Rivas JM; Sanz MA; Feliu E; Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744 [TBL] [Abstract][Full Text] [Related]
30. [Treatment of acute lymphoblastic leukemias in adults]. Wrzesień-Kuś A; Krykowski E Przegl Lek; 1997; 54(9):639-46. PubMed ID: 9501686 [TBL] [Abstract][Full Text] [Related]
31. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia. Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617 [TBL] [Abstract][Full Text] [Related]
37. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL. Ortega JJ; Ribera JM; Oriol A; Bastida P; González ME; Calvo C; Egurbide I; Hernández Rivas JM; Rivas C; Alcalá A; Besalduch J; Maciá J; Gardella S; Carnero M; Lite JM; Casanova F; Martinez M; Fontanillas M; Feliu E; San Miguel JF; Haematologica; 2001 Jun; 86(6):586-95. PubMed ID: 11418367 [TBL] [Abstract][Full Text] [Related]
38. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96. Ribera JM; Oriol A; Sanz MA; Tormo M; Fernández-Abellán P; del Potro E; Abella E; Bueno J; Parody R; Bastida P; Grande C; Heras I; Bethencourt C; Feliu E; Ortega JJ J Clin Oncol; 2008 Apr; 26(11):1843-9. PubMed ID: 18398150 [TBL] [Abstract][Full Text] [Related]
39. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055 [TBL] [Abstract][Full Text] [Related]
40. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia]. Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]